Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with Vistusertib or Capivasertib in Recurrent Endometrial, TNBC, and Ovarian Cancers
NCT02208375Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2014
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib, vistusertib and capivasertib in endometrial cancer (EC), triple-negative breast cancer (TNBC), ovarian cancer and 2 more (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2014; status: active, not recruiting.
02
Drugs
olaparibvistusertibcapivasertib
03
Conditions
endometrial cancer (EC)triple-negative breast cancer (TNBC)ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02208375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208375.